Sotera Health (NASDAQ:SHC) Earns “Outperform” Rating from Royal Bank of Canada

Sotera Health (NASDAQ:SHC)‘s stock had its “outperform” rating restated by stock analysts at Royal Bank of Canada in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $17.00 price objective on the stock. Royal Bank of Canada’s target price would suggest a potential upside of 32.61% from the company’s previous close.

A number of other equities research analysts also recently weighed in on the company. Barclays lifted their target price on Sotera Health from $14.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, August 6th. Citigroup boosted their target price on shares of Sotera Health from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Sotera Health has an average rating of “Moderate Buy” and a consensus target price of $16.50.

Sotera Health Stock Up 3.3 %

Sotera Health stock opened at $12.82 on Thursday. The firm has a 50 day moving average price of $15.61 and a two-hundred day moving average price of $13.94. The company has a debt-to-equity ratio of 4.91, a quick ratio of 2.61 and a current ratio of 2.88. Sotera Health has a 52-week low of $10.71 and a 52-week high of $17.44. The firm has a market cap of $3.63 billion, a price-to-earnings ratio of 51.28 and a beta of 2.08.

Sotera Health (NASDAQ:SHC) last released its earnings results on Tuesday, November 5th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). Sotera Health had a net margin of 6.31% and a return on equity of 42.27%. The firm had revenue of $285.47 million during the quarter, compared to analyst estimates of $278.64 million. During the same quarter in the previous year, the firm earned $0.18 EPS. Sotera Health’s quarterly revenue was up 8.5% on a year-over-year basis. Equities analysts predict that Sotera Health will post 0.61 EPS for the current year.

Insider Buying and Selling at Sotera Health

In other Sotera Health news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of Sotera Health stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $15.03, for a total transaction of $150,300,000.00. Following the completion of the transaction, the director now owns 49,215,301 shares in the company, valued at approximately $739,705,974.03. The trade was a 16.89 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 55.12% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of SHC. Neo Ivy Capital Management purchased a new stake in Sotera Health in the 3rd quarter valued at $720,000. Geode Capital Management LLC grew its stake in shares of Sotera Health by 19.4% in the 3rd quarter. Geode Capital Management LLC now owns 2,755,391 shares of the company’s stock worth $46,026,000 after acquiring an additional 447,186 shares in the last quarter. Barclays PLC raised its holdings in shares of Sotera Health by 169.8% in the third quarter. Barclays PLC now owns 473,597 shares of the company’s stock valued at $7,909,000 after purchasing an additional 298,085 shares during the last quarter. Public Employees Retirement System of Ohio lifted its position in shares of Sotera Health by 14.3% during the third quarter. Public Employees Retirement System of Ohio now owns 54,706 shares of the company’s stock valued at $914,000 after purchasing an additional 6,826 shares in the last quarter. Finally, iSAM Funds UK Ltd bought a new position in shares of Sotera Health during the third quarter valued at about $259,000. Institutional investors own 91.03% of the company’s stock.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.